External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Roche and Genentech at

2025 ASCO® Gastrointestinal Cancers Symposium

January 23 - January 25

San Francisco, USA

conferences.asco.org

Add to calendar

Medical Materials

Agenda

Coming soon

07:30 PM

Duration 90mins San Francisco, USA

KIRROS: A phase II trial in progress of first-line atezolizumab (atezo) with or without bevacizumab (bev) in patients with unresectable hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis

Kristen Spencer, Amit Singal, Laura Kulik, Augusto Villanueva, Renuka Iyer, Shilpa Chakalakal, Rucha Kothari, Jinnie Ko, Norelle Reilly, Thomas Stark, Anthony El-Khoueiry

Oncology | Gastric Cancer - Gastrointestinal Cancer

Add to calendar

Duration 90mins San Francisco, USA

Real-world (RW) experience with atezolizumab + bevacizumab (A+B) for the treatment of unresectable hepatocellular carcinoma (uHCC): A multicenter study

Maen Abdelrahim1, Abdullah Esmail1, Richard D. Kim2, Sukeshi Patel Arora3, Junaid Arshad4, Ioannis A. Kournoutas5, Conor D. O’Donnell5, Todor I. Totev6, Amie Tan7, Fan Mu6, Shravanthi M. Seshasayee6, Sairy Hernandez7, Nguyen H. Tran5

Oncology | Gastric Cancer - Gastrointestinal Cancer

Add to calendar

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.